|
1
|
Simonsen DF, Farkas DK, Søgaard M,
Horsburgh CR, Sørensen HT and Thomsen RW: Tuberculosis and risk of
cancer: A Danish nationwide cohort study. Int J Tuberc Lung Dis.
18:1211–1219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song Z, Shi Y, Han Q and Dai G:
Endothelial growth factor receptor-targeted and reactive oxygen
species-responsive lung cancer therapy by docetaxel and resveratrol
encapsulated lipid-polymer hybrid nanoparticles. Biomed
Pharmacother. 105:18–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carney DN: Lung cancer-time to move on
from chemotherapy. N Engl J Med. 346:126–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murren JR, Durivage HJ, Rosenberg AH, Chen
Y, Del Prete SA, Murphy GJ, Buzaid AC and Hait WN: Cisplatin,
doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of
metastatic non-small cell lung cancer. Limited activity of an
aggressive chemotherapy regimen. Am J Clin Oncol. 17:239–241. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Z, Song M, He Z, Zong L, Jiang B, Zhang
T and Hu Z: Comparison of quick recovery outcome of inhalable
doxorubicin and cisplatin in lung cancer patients: A randomized,
double-blind, single-center trial. Drug Deliv Transl Res.
8:985–993. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Cheng H, Han L, Qiang Z, Zhang X,
Gao W, Zhao K and Song Y: Synergistic combination therapy of lung
cancer using paclitaxel- and triptolide-coloaded lipid-polymer
hybrid nanoparticles. Drug Des Devel Ther. 12:3199–3209. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Prabhu VV and Devaraj N: Epidermal growth
factor receptor tyrosine kinase: A potential target in treatment of
non-small-cell lung carcinoma. J Environ Pathol Toxicol Oncol.
36:151–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pancewicz-Wojtkiewicz J: Epidermal growth
factor receptor and notch signaling in non-small-cell lung cancer.
Cancer Med. 5:3572–3578. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schrank Z, Chhabra G, Lin L, Iderzorig T,
Osude C, Khan N, Kuckovic A, Singh S, Miller RJ and Puri N: Current
molecular-targeted therapies in NSCLC and Their mechanism of
resistance. Cancers (Basel). 10(pii): E2242018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gerber DE: Targeted therapies: A new
generation of cancer treatments. Am Fam Physician. 77:311–319.
2008.PubMed/NCBI
|
|
14
|
Tsai WH, Yu KH, Huang YC and Lee CI:
EGFR-targeted photodynamic therapy by curcumin-encapsulated
chitosan/TPP nanoparticles. Int J Nanomedicine. 13:903–916. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iram S, Zahera M, Khan S, Khan I, Syed A,
Ansary AA, Ameen F, Shair OHM and Khan MS: Gold nanoconjugates
reinforce the potency of conjugated cisplatin and doxorubicin.
Colloids Surf B Biointerfaces. 160:254–264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun TM, Du JZ, Yao YD, Mao CQ, Dou S,
Huang SY, Zhang PZ, Leong KW, Song EW and Wang J: Simultaneous
delivery of siRNA and paclitaxel via a ‘two-in-one’ micelleplex
promotes synergistic tumor suppression. ACS Nano. 5:1483–1494.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Browning RJ, Reardon PJT, Parhizkar M,
Pedley RB, Edirisinghe M, Knowles JC and Stride E: Drug delivery
strategies for platinum-based chemotherapy. ACS Nano. 11:8560–8578.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oberoi HS, Nukolova NV, Kabanov AV and
Bronich TK: Nanocarriers for delivery of platinum anticancer drugs.
Adv Drug Deliv Rev. 65:1667–1685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marullo R, Werner E, Degtyareva N, Moore
B, Altavilla G, Ramalingam SS and Doetsch PW: Cisplatin induces a
mitochondrial-ROS response that contributes to cytotoxicity
depending on mitochondrial redox status and bioenergetic functions.
PLoS One. 8:e811622013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramasamy T, Tran TH, Choi JY, Cho HJ, Kim
JH, Yong CS, Choi HG and Kim JO: Layer-by-layer coated
lipid-polymer hybrid nanoparticles designed for use in anticancer
drug delivery. Carbohydr Polym. 102:653–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ruttala HB, Ramasamy T, Gupta B, Choi HG,
Yong CS and Kim JO: Multiple polysaccharide-drug complex-loaded
liposomes: A unique strategy in drug loading and cancer targeting.
Carbohydr Polym. 173:57–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo S, Wang Y, Miao L, Xu Z, Lin CM, Zhang
Y and Huang L: Lipid-coated Cisplatin nanoparticles induce
neighboring effect and exhibit enhanced anticancer efficacy. ACS
Nano. 7:9896–9904. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Han L, Liu J, Han S, Chen Z and
Jiang L: Co-delivery of paclitaxel and TOS-cisplatin via
TAT-targeted solid lipid nanoparticles with synergistic antitumor
activity against cervical cancer. Int J Nanomedicine. 12:955–968.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kou CH, Han J, Han XL, Zhuang HJ and Zhao
ZM: Preparation and characterization of the Adriamycin-loaded
amphiphilic chitosan nanoparticles and their application in the
treatment of liver cancer. Oncol Lett. 14:7833–7841.
2017.PubMed/NCBI
|
|
25
|
Bohl Kullberg E, Bergstrand N, Carlsson J,
Edwards K, Johnsson M, Sjöberg S and Gedda L: Development of
EGF-conjugated liposomes for targeted delivery of boronated
DNA-binding agents. Bioconjug Chem. 13:737–743. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qiu J, Cai G, Liu X and Ma D:
αvβ3 integrin receptor specific peptide
modified, salvianolic acid B and panax notoginsenoside loaded
nanomedicine for the combination therapy of acute myocardial
ischemia. Biomed Pharmacother. 96:1418–1426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Zhang P and Zhu T: Ovarian
carcinoma biological nanotherapy: Comparison of the advantages and
drawbacks of lipid, polymeric, and hybrid nanoparticles for
cisplatin delivery. Biomed Pharmacother. 109:475–483. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tan S and Wang G: Redox-responsive and
pH-sensitive nanoparticles enhanced stability and anticancer
ability of erlotinib to treat lung cancer in vivo. Drug Des Devel
Ther. 11:3519–3529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan S and Wang G: Lung cancer targeted
therapy: Folate and transferrin dual targeted, glutathione
responsive nanocarriers for the delivery of cisplatin. Biomed
Pharmacother. 102:55–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duan W and Liu Y: Targeted and synergistic
therapy for hepatocellular carcinoma: Monosaccharide modified lipid
nanoparticles for the co-delivery of doxorubicin and sorafenib.
Drug Des Devel Ther. 12:2149–2161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang F, Li A, Liu H and Zhang H: Gastric
cancer combination therapy: Synthesis of a hyaluronic acid and
cisplatin containing lipid prodrug coloaded with sorafenib in a
nanoparticulate system to exhibit enhanced anticancer efficacy and
reduced toxicity. Drug Des Devel Ther. 12:3321–3333. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Z, Wei Y, Fang G, Hong D, An L, Jiao
T, Shi Y and Zang A: Colorectal cancer combination therapy using
drug and gene co-delivered, targeted poly(ethylene
glycol)-ε-poly(caprolactone) nanocarriers. Drug Des Devel Ther.
12:3171–3180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao Z, Li Z, Yan J and Wang P: Irinotecan
and 5-fluorouracil-co-loaded, hyaluronic acid-modified
layer-by-layer nanoparticles for targeted gastric carcinoma
therapy. Drug Des Devel Ther. 11:2595–2604. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh A, Xu J, Mattheolabakis G and Amiji
M: EGFR-targeted gelatin nanoparticles for systemic administration
of gemcitabine in an orthotopic pancreatic cancer model.
Nanomedicine. 12:589–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gill MR, Menon JU, Jarman PJ, Owen J,
Skaripa-Koukelli I, Able S, Thomas JA, Carlisle R and Vallis KA:
111In-labelled polymeric nanoparticles incorporating a
ruthenium-based radiosensitizer for EGFR-targeted combination
therapy in oesophageal cancer cells. Nanoscale. 10:10596–10608.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kuai JH, Wang Q, Zhang AJ, Zhang JY, Chen
ZF, Wu KK and Hu XZ: Epidermal growth factor receptor-targeted
immune magnetic liposomes capture circulating colorectal tumor
cells efficiently. World J Gastroenterol. 24:351–359. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ,
Radovic-Moreno AF, Alexis F, Langer R and Farokhzad OC:
Self-assembled lipid-polymer hybrid nanoparticles: A robust drug
delivery platform. ACS Nano. 2:1696–1702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
You P, Yuan R and Chen C: Design and
evaluation of lidocaine- and prilocaine-coloaded nanoparticulate
drug delivery systems for topical anesthetic analgesic therapy: A
comparison between solid lipid nanoparticles and nanostructured
lipid carriers. Drug Des Devel Ther. 11:2743–2752. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang S, Li J, Hu S, Wu F and Zhang X:
Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000
succinate-modified, tanshinone IIA-loaded lipid-polymeric
nanocarriers for the targeted therapy of myocardial infarction. Int
J Nanomedicine. 13:4045–4057. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miao JF, Peng YF, Chen S, Gao WJ, Yang QX,
Zhu P, Guo J, Tao J, Luo L, Zhang Y and Ling Y: A novel harmine
derivative,
N-(4-(hydroxycarbamoyl)benzyl)-1-(4-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide
(HBC), as histone deacetylase inhibitor: In vitro
antiproliferation, apoptosis induction, cell cycle arrest, and
antimetastatic effects. Eur J Pharmacol. 824:78–88. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nishikawa K, Asai T, Shigematsu H, Shimizu
K, Kato H, Asano Y, Takashima S, Mekada E, Oku N and Minamino T:
Development of anti-HB-EGF immunoliposomes for the treatment of
breast cancer. J Control Release. 160:274–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gawde KA, Sau S, Tatiparti K, Kashaw SK,
Mehrmohammadi M, Azmi AS and Iyer AK: Paclitaxel and di-fluorinated
curcumin loaded in albumin nanoparticles for targeted synergistic
combination therapy of ovarian and cervical cancers. Colloids Surf
B Biointerfaces. 167:8–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang H, Sun G, Zhang Z and Ou Y:
Transcription activator, hyaluronic acid and tocopheryl succinate
multi-functionalized novel lipid carriers encapsulating etoposide
for lymphoma therapy. Biomed Pharmacother. 91:241–250. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cui T, Zhang S and Sun H: Co-delivery of
doxorubicin and pH-sensitive curcumin prodrug by
transferrin-targeted nanoparticles for breast cancer treatment.
Oncol Rep. 37:1253–1260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu B, Yu L and Yue Q: Co-delivery of
vincristine and quercetin by nanocarriers for lymphoma combination
chemotherapy. Biomed Pharmacother. 91:287–294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mandal B, Bhattacharjee H, Mittal N, Sah
H, Balabathula P, Thoma LA and Wood GC: Core-shell-type
lipid-polymer hybrid nanoparticles as a drug delivery platform.
Nanomedicine. 9:474–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
